Merck KGaA partners with BenevolentAI and Exscientia for AI-driven drug discovery

Merck KGaA has entered into separate AI drug discovery partnerships with BenevolentAI and Exscientia, focusing on targets in oncology, neurology, and immunology. Exscientia will receive $20 million upfront for each of the three projects, with a total deal value of $674 million across all milestones. BenevolentAI will receive a low double-digit million dollar payment upfront, potentially worth $594 million, and both companies may receive tiered royalties on future sales.